[THE INVESTOR] On Oct. 13, Genexine (095700) declined 3.6% to 42,800 won (US$37.68). It had declined 13.14% through the past month. Standard deviation, which indicates variableness, records 2.5% over the same period of time over one month.
Compared with its close competitors within the same industry, KOSDAQ, even though the monthly earnings rate of Genexine was negative, its volatility for 1 month was relatively higher among its peer group. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -5.2%. Though the volatility was high, low decreasing rate of stock price lead that the return-on-risk remained around the average of its peer group. However, compared with the KOSDAQ industry, the return-on-risk is below the industrial mean, -0.1, and thus it is hard to say that the industrial comparison performance was positive.
Yesterday, institutions and foreigners sold 4,197 shares and 6,486 shares. As a shareholding sum by investor group for the past four weeks, foreigners have bought 45,790 shares with a maintenance of shareholding and institutions have bought 38,118 shares with trending trade. However, during the same period, individuals have sold 83,908 shares with a decreasing position.
| Cumulated shareholdings per investor group (1Mo) | Total shareholdings per investor group | |
 |
 |
By HeRo (hero@heraldcorp.com)
This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.
